New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy. Allergy Chinthrajah, R. S., Sindher, S. B., Nadeau, K. C., Leflein, J. G., Spergel, J. M., Petroni, D. H., Jones, S. M., Casale, T. B., Wang, J., Carr, W. W., Shreffler, W. G., Wood, R. A., Wambre, E., Liu, J., Akinlade, B., Atanasio, A., Orengo, J. M., Hamilton, J. D., Kamal, M. A., Hooper, A. T., Patel, K., Laws, E., Mannent, L. P., Adelman, D. C., Ratnayake, A., Radin, A. R. 2024Abstract
Peanut allergy is a common, life-threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)-4/IL-13, enhances the efficacy of oral immunotherapy (OIT) AR101 in pediatric patients with peanut allergy.A Phase II, multicenter, randomized, double-blind study was conducted in the USA (NCT03682770) in pediatric patients (6-=?17?years old) with confirmed peanut allergy. Patients were randomized 2:1 to receive dupilumab + OIT or placebo + OIT during a 28-40-week up-dosing period. Patients in the dupilumab + OIT group were re-randomized 1:1 and received dupilumab + OIT or placebo + OIT during 24-week OIT maintenance, undergoing a 2044?mg (cumulative) of peanut protein double-blind, placebo-controlled food challenge (DBPCFC) following up-dosing, maintenance, and at 12-week post-treatment follow-up.The study enrolled 148 patients, 123 of whom were included in the modified full analysis set, with a mean age of 11.1?years. Dupilumab + OIT treatment (n?=?84) led to a 20.2% increase (p?
View details for DOI 10.1111/all.16420
View details for PubMedID 39673367